Ab&B Biotech

About Ab&B Biotech

Ab&B Bio-Tech Co., Ltd. JS is a publicly-traded vaccine company based in Taizhou, China, established in 2015. The company focuses on the full cycle of human vaccine development, from research and manufacturing to the commercialization of its products. It operates with a mission to introduce global vaccine advancements to China and, in turn, supply Chinese-developed vaccines to the international market. The business model centers on developing and selling vaccines directly, targeting both domestic and international markets, including North and South America, Africa, and Southeast Asia.

The company's core product is a quadrivalent influenza virus subunit vaccine, which is already commercially available for individuals aged three and older. A pediatric version for children aged 6-35 months has completed Phase III clinical trials. Another key pipeline product is a lyophilized human rabies vaccine. Ab&B Bio-Tech's development pipeline is extensive, featuring 11 other vaccine candidates that address various diseases and employ diverse technologies such as viral, bacterial, conjugate, recombinant subunit, and mRNA platforms. Notably, the company has developed a broad-spectrum mRNA vaccine targeting the smallpox virus. The company's quadrivalent influenza vaccine utilizes an advanced subunit process that differentiates it in the marketplace.

Founded in 2015, Ab&B Bio-Tech has achieved significant financial milestones. In August 2021, it raised $92.8 million in a Series C funding round with investors including Green Pine Capital Partners and HLC. The company went public with an initial public offering (IPO) on the Hong Kong Stock Exchange in August 2025, raising approximately $55 million. This IPO was notably oversubscribed by retail investors, indicating strong market interest. The company has been recognized as a "Potential Unicorn Enterprise" and a "Gazelle Enterprise" in the Jiangsu High-Tech Industrial Development Zone.